Rigel Pharmaceuticals, Inc.
RIGL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $1 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $1 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -31.7% | 90.7% | -7.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 93.2% | 95.6% | 91.7% | 89.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 43.4% | 61.4% | 26.2% | 30.9% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 40.2% | 58.6% | 21.5% | 24.9% |
| EPS Diluted | 1.457 | 3.28 | 0.63 | 0.8 |
| % Growth | -55.6% | 420.6% | -21.3% | – |
| Operating Cash Flow | $0 | $0 | -$0 | $0 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | $0 | $0 | -$0 | $0 |